Study Investigating the Association of NP137 With Atezolizumab-Bevacizumab Combination in First Line in Unresectable HCC

NCT05546879 · clinicaltrials.gov ↗

PHASE1

Phase

SUSPENDED

Status

43

Enrollment

OTHER

Sponsor class

Stopped Number of patients achieved and treatment ongoing

Conditions

Hepatocellular Carcinoma

Interventions

DRUG: NP137
DRUG: Atezolizumab
DRUG: Bevacizumab

Sponsor

University Hospital, Grenoble

Collaborators

[object Object]